**Trader sentiment on IPOs before 2027 reflects a selective window amid macro pressures.** Multiple U.S. listings are scheduled for October and November 2026, including Iambic Therapeutics and City Therapeutics in mid-October plus Anthropic’s targeted mid-November debut at a potential $1.8–2 trillion valuation. Recent data show continued filings and pricings in biotech and AI infrastructure, yet several high-profile deals including Oura have been postponed or withdrawn due to volatility, the Federal Reserve’s September rate hike, and elevated Treasury yields. Hong Kong’s market remains robust with strong A+H and specialist tech proceeds, while U.S. activity stays concentrated among scaled issuers. Key near-term catalysts include Anthropic’s roadshow timing and year-end economic releases that could shift risk appetite before year-end.